This content is machine translated BRAFV600 stage IV melanoma Targeted therapy: “real world” data on encorafenib plus binimetinib The BERING-Melanoma multicenter study is monitoring the use of encorafenib with binimetinib in the first- and second-line setting* in patients with advanced BRAFV600-mutated malignant melanoma in everyday care in Germany, Austria,…
View Post 8 min This content is machine translated Plasma cell myeloma Preferences in myeloma treatment in Switzerland 2018 With the approval of several new drugs, the treatment spectrum for second-line therapy of plasma cell myeloma has been expanded. In parallel, established treatment concepts, predominantly in first-line treatment, were…
View Post 6 min This content is machine translated DGHO in Vienna Prostate and breast cancer: the future belongs to combined therapies Treatment options are often limited in both prostate and breast carcinoma. The search for new effective drugs and combination therapies is therefore the primary goal of current studies.
View Post 3 min This content is machine translated Personalized therapy for lung tumors Has platinum-containing first-line therapy had its day? Personalized immunotherapy is on track to replace chemotherapy in first-line non-small cell lung cancer. However, this only works for every second patient. Chemo vs. immuno-oncology – who will win the…
View Post 4 min This content is machine translated Annual Meeting DGHO, OeGHO, SGMO and SGH+SSH in Stuttgart, Germany Update hepatocellular carcinoma – news from the system therapy In hepatocellular carcinoma, an increase in incidence has been observed in industrialized countries. HCC patients have at least two diseases, namely carcinoma as well as severe liver disease. The interaction…
View Post 6 min This content is machine translated ESMO 2017 in Madrid Blocking the “escape route” for the tumor Upsets in first-line therapy of non-small cell EGFR-mutated lung cancer are imminent. With the FLAURA trial, osimertinib is confidently presenting itself for the first time as a treatment option for…
View Post 4 min This content is machine translated PD1/PD-L1 in second-line therapy for metastatic NSCLC. The agony of choice The treatment of bronchial carcinoma is greatly changed by immunotherapy. Current developments will lead to an adjustment of our therapy algorithms in the coming months.
View Post 6 min This content is machine translated 19th Zurich Cardiovascular Day Putting patients through their paces The Cardiovascular Day at the Marriott Hotel in Zurich provided a broad overview of the three most important organs in the circulatory system: heart, kidney and brain. In addition to…
View Post 7 min This content is machine translated HER2-positive breast carcinoma New substances enable targeted therapy The HER2 receptor belongs to the family of four transmembrane receptor tyrosine kinases (EGFR/HER1, HER2, HER3, and HER4) that influence cell growth, differentiation, and survival. Overexpression of HER2 occurs in…
